NeonMind to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference Psychedelics Investing
Longer-term Data for Kite's Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis Biotech Investing
IMBRUVICA® Plus VENCLEXTA®/VENCLYXTO® Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia Phase 3 GLOW Study Biotech Investing
Perimeter Medical Imaging AI to Participate in Panel Discussion "Innovations in Breast Cancer Detection, Surgery and Treatment" at the Lytham Partners Summer 2021 Investor Conference Medical Device Investing
Naturally Splendid Announces Select Denny's Canada Restaurants to Offer NATERA Meat Alternative Entrees Biotech Investing
Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent Beta Thalassemia Biotech Investing
New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment Biotech Investing
Silo Wellness: Revenue Generating and Vertically Integrated Wellness Products and Retreats Life Science Investing News
U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C Biotech Investing
